Harvard Office of Technology Development

Modulating the Blood-Brain Barrier (BBB) to enable delivery of drugs and development of therapeutics

The blood–brain barrier (BBB) helps maintain a constant, optimal environment for neuronal function through a combination of barriers and selective transport systems that regulate the passage of wanted and unwanted molecules. While important for…

Investigators

Chenghua Gu

Anti-cancer Therapeutic Strategy Targeting Ammonium Metabolism

Cancer has long been recognized as a disease of altered cellular metabolism as cancer cells have an abnormally high demand for nutrients to support their growth and proliferation. However, targeting cancer cell metabolism has not been seriously…

Investigators

Marcia C. Haigis
Jessica Brooke Spinelli

Hba-a1 knockout mice

Homozygous Hba-a1 (hemoglobin alpha, adult chain 1) knockout mice (129S-Hba-a1tm1Led/J) were developed by HHMI Investigator Dr. Philip Leder and his lab at Harvard Medical School. While the mice are viable and fertile, they develop anemia with…

Investigators

Philip Leder

Trpa1 conditional knockout mice

The mouse strain 129S-Trpa1tm2Kykw/J was developed by Kelvin Kwan in the laboratory of HHMI Investigator David Corey at Harvard Medical School. Trpa1 conditional knockout animals were generated by flanking the exons that code for the pore domain of…

Investigators

Kelvin Y. Kwan
David P. Corey

TRPA1 knockout mice developed in the laboratory of Professor David Corey

Homozygous Transient Receptor Potential Cation Channel Subfamily A Member 1 (TRPA1) mutant mice (B6;129P-Trpa1tm1Kykw/J, also known as Trpa1 KO) were developed by HHMI Investigator David Corey at Harvard Medical School. They exhibit abnormal…

Investigators

David P. Corey

Targeting fatty acid oxidation for treatment of cancer, including AML, prostate, breast and colon cancers

Several cancers are characterized by slow glycolysis and rely on non-glycolytic pathways such as fatty acid oxidation (FAO) as their main source of energy. While dependency of cancer cells on FAO has been known, the underlying mechanistic…

Investigators

Marcia C. Haigis

Intracellular delivery of proteins: Aurin 1.2, an efficient non-endosomal protein delivery platform

To fully realize the therapeutic potential of proteins, exogenous proteins need to access intracellular targets. Since the vast majority of proteins cannot spontaneously cross cell membranes, a range of delivery platforms have been developed. These…

Investigators

David R. Liu

Using evolutionary coupling methodology and other unique computational biology tools to advance pharmaceutical development

The prediction of drug effects is a long-standing challenge in the biomedical data community and pharmaceutical industry. As new candidate target genes emerge from successful CRISPR and GWAS screens, assessing ‘anti-targets’ and exploiting…

Investigators

Debora Marks

Liquid biopsy-based predictive platform for early cancer detection and drug discovery

Recognition and management of individuals susceptible to disease are critical for patient care. However, identification of these patients is very challenging, especially in oncology. Dr. Peter Park and his group at the Department of Biomedical…

Investigators

Peter Park

First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes

First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes. Professor David Liu and a multidisciplinary research team have recently discovered and optimized of a series of small molecules (<550 Da, IC50 = 1…

Investigators

David R. Liu
Juan Pablo Maianti